CTOs on the Move


 
PaxVax is a privately held, fully integrated vaccine company, based in Redwood City, California, USA. Established in 2007, in response to the global threat of the H5N1 pandemic, our founders set out to develop and commercialize an innovative vaccine technology in a socially responsible manner for global impact. Our founding principles were to enable geographically distributed manufacturing of affordable, self-administered oral vaccines against infectious diseases such as influenza. Since then, we have expanded our capabilities and technologies to address unmet vaccine needs against endemic diseases in developing countries, for travelers to disease-laden areas and in biodefense. Our clinical stage portfolio ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.paxvax.com
  • 900 Veterans Boulevard Suite 500
    Redwood City, CA USA 94063
  • Phone: 650.847.1075

Executives

Name Title Contact Details

Funding

PaxVax raised $105M on 12/08/2015

Similar Companies

Galileo Life

At Galileo Life, our goal is nothing short of a revolution in the way that healthcare is talked about and delivered. Through the establishment of a dedicated and professional network of Galileo Smart Clinics throughout the country, our vision is the development of a national-level holistic health services and wellness platform specializing in assessment, diagnostic, home-monitoring, and treatment services. The Healthcare Renaissance is here, and Galileo Life Sciences intends to herald the change in Healthcare and re-imagine Healthcare options. Galileo Life Sciences is about the pursuit of alternative solutions both in addition to, and outside of the current Western medical healthcare paradigm. We believe in taking the best of the conventional and combining it with what nature has provided - and what droves of scientific research continues to uncover and confirm - to help us heal, relieve pain, improve sleep, alleviate anxiety, increase appetite, offset the side effects of powerful pharmacological and medical treatments, and much more. Galileo Life Sciences extends an invitation to all practitioners and entrepreneurs in the Healthcare sector, to join us and become part of the bold and rapid global movement to ensure that healthcare is accessible by all in the world.

Cyagen

Cyagen Biosciences is an emerging and innovative biotechnology company that specializes in custom murine model generation, DNA vector construction and viral packaging services. We also offer a comprehensive catalog of stem cell lines, cell culture reagents and growth factors. Our rapidly expanding services portfolio features VectorBuilder – an online DNA vector construction platform designed to make tedious cloning projects obsolete. Let us provide the knowledge and resources to move your project forward, and get you back to discovery!

Surrozen

Surrozen is a biotechnology company focused on discovering and developing novel regenerative medicines with a focus on unlocking the powerful self-renewal properties of the body through specific control of the Wnt signaling pathway.

Bionest Partners

Bionest Partners is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Atomwise

Atomwise is a preclinical pharma company revolutionizing how drugs are discovered with AI. Atomwise has strengthened its drug discovery and development expertise by expanding its Board of Directors and creating a Scientific Advisory Board (SAB). These appointments signal a critical milestone for Atomwise as the company focuses on its own internal pipeline. We invented the use of deep learning for structure-based drug discovery, today developing a pipeline of small-molecule drug candidates advancing into preclinical studies. Our AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. We are tackling over 600 unique disease targets with more than 250 partners around the world, including leading pharmaceutical, agrochemical, and emerging biotechnology companies. Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster.